MCKNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends March 31
MCKESSON CORP
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$1010.43+5.59 (+0.56%)
Close on Oct 19, 2026
- Market cap
- $120.44B
- P/E (TTM)
- 27.1
- Dividend yield
- 0.31%
MCKESSON CORP revenue by segment
By business segment
| Revenue | Q1 27 | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North American Pharmaceutical | $86.77B | $79.12B | $88.32B | $86.48B | $82.73B | $76.94B | $81.20B | $80.02B | – | – | – | – | 82.3% | +4.9% |
| Oncology & Multispecialty | $14.22B | $12.71B | $13.01B | $12.04B | $10.66B | $9.43B | $9.49B | $9.16B | – | – | – | – | 13.5% | +33.4% |
| Medical-Surgical Solutions | $2.82B | $2.87B | $2.99B | $2.95B | $2.70B | $2.85B | $2.95B | $2.95B | $2.64B | $2.83B | $3.03B | $2.83B | 2.7% | +4.4% |
| Prescription Technology Solutions | $1.57B | $1.50B | $1.50B | $1.38B | $1.43B | $1.34B | $1.37B | $1.27B | $1.24B | $1.18B | $1.21B | $1.14B | 1.5% | +9.2% |
| International | – | – | – | – | $3.74B | $3.46B | $3.86B | $3.71B | $3.69B | $3.55B | $3.64B | $3.48B | – | – |
| U.S. Pharmaceutical | – | – | – | – | $89.95B | $83.17B | $87.11B | $85.73B | $71.72B | $68.79B | $73.02B | $69.77B | – | – |
| Prescription Technology Solutions | – | – | – | – | – | – | – | – | – | – | – | $1.14B | – | – |
| Corporate | – | – | – | – | – | – | $4.00M | $3.00M | – | – | $0 | $0 | – | – |
| Operating income | Q1 27 | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical-Surgical Solutions | – | – | – | – | – | – | $269.00M | $89.00M | $188.00M | – | $268.00M | $244.00M | – |
| Prescription Technology Solutions | – | – | – | – | – | – | $219.00M | $205.00M | $203.00M | – | $178.00M | $238.00M | – |
| International | – | – | – | – | – | – | $111.00M | -$508.00M | $90.00M | – | $126.00M | $66.00M | – |
| U.S. Pharmaceutical | – | – | – | – | – | – | $854.00M | $1.08B | $781.00M | – | $307.00M | $593.00M | – |
| Prescription Technology Solutions | – | – | – | – | – | – | – | – | – | – | – | $238.00M | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Mckesson's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.